Cargando…

Outcome in serous ovarian cancer is not associated with LATS expression

BACKGROUND: Large tumor suppressor (LATS) proteins are putative tumor suppressors and poorly expressed associated with poor outcome in many cancers. A recent immunohistochemistry study showed that LATS protein expression correlated with poor outcome in serous ovarian cancer. MATERIALS AND METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montavon, Céline, Stricker, Gregor R., Schoetzau, Andreas, Heinzelmann-Schwarz, Viola, Jacob, Francis, Fedier, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800864/ https://www.ncbi.nlm.nih.gov/pubmed/31586262 http://dx.doi.org/10.1007/s00432-019-03037-4

Ejemplares similares

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer
por: Montavon Sartorius, Céline, et al.
Publicado: (2018)

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers
por: Montavon, Celine, et al.
Publicado: (2018)

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
por: Jacob, Francis, et al.
Publicado: (2020)

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients
por: Pochechueva, Tatiana, et al.
Publicado: (2016)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
por: Vetter, Marcus, et al.
Publicado: (2022)

Tumor-Associated Glycans and Their Role in Gynecological Cancers: Accelerating Translational Research by Novel High-Throughput Approaches
por: Pochechueva, Tatiana, et al.
Publicado: (2012)

An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting
por: Vigo, Francesco, et al.
Publicado: (2021)

Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients
por: Kohler, Reto S., et al.
Publicado: (2016)

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells
por: Jacob, Francis, et al.
Publicado: (2014)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma
por: Anugraham, Merrina, et al.
Publicado: (2017)

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
por: Coelho, Ricardo, et al.
Publicado: (2022)

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers
por: Sartorius, Céline Montavon, et al.
Publicado: (2018)

L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy
por: Zeiter, Deborah, et al.
Publicado: (2021)

Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines
por: Jacob, Francis, et al.
Publicado: (2013)

Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis
por: Huang, Yen-Lin, et al.
Publicado: (2020)

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer
por: Saner, Flurina AM, et al.
Publicado: (2019)

Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial
por: Amstad, Gabriela, et al.
Publicado: (2022)

Reliable in vitro studies require appropriate ovarian cancer cell lines
por: Jacob, Francis, et al.
Publicado: (2014)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
por: Vias, Maria, et al.
Publicado: (2023)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells
por: Ford, Caroline E., et al.
Publicado: (2013)

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients
por: Pochechueva, Tatiana, et al.
Publicado: (2017)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

A forgotten disease: Pelvic congestion syndrome as a cause of chronic lower abdominal pain
por: Jurga-Karwacka, Agnieszka, et al.
Publicado: (2019)

Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
por: Buehler, Michelle, et al.
Publicado: (2013)

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
por: Hanker, L. C., et al.
Publicado: (2021)

Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high‐grade serous ovarian cancer
por: Zhang, Guodong, et al.
Publicado: (2021)

The glycosphingolipid P(1) is an ovarian cancer-associated carbohydrate antigen involved in migration
por: Jacob, F, et al.
Publicado: (2014)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation
por: Ravikumar, Gayatri, et al.
Publicado: (2013)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
por: Heinzelmann-Schwarz, Viola, et al.
Publicado: (2020)

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival
por: Lisowska, Katarzyna M., et al.
Publicado: (2016)

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker
por: HEINZELMANN-SCHWARZ, VIOLA A., et al.
Publicado: (2014)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies
por: Schwab, Fabienne D., et al.
Publicado: (2022)

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
por: Baettig, Florence, et al.
Publicado: (2019)

High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer
por: Zhang, Mei, et al.
Publicado: (2020)

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
por: Song, Honglin, et al.
Publicado: (2021)

Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer
por: Dondi, Arthur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fi2g43nods1c9p8vq2mv6npohr